Literature DB >> 26170906

Effect of transgenic human insulin-like growth factor-1 on spinal motor neurons following peripheral nerve injury.

Jiaxiang Gu1, Hongjun Liu1, Naichen Zhang1, Heng Tian1, Junbo Pan1, Wenzhong Zhang1, Jingcheng Wang1.   

Abstract

The aim of the present study was to observe the protective effect of exogenous human insulin-like growth factor-1 (hIGF-1) on spinal motor neurons, following its local transfection into an area of peripheral nerve injury. A total of 90 male Wistar rats that had been established as sciatic nerve crush injury models were randomly divided into three groups: hIGF-1 treatment, sham-transfected control and blank control groups. The different phases of hIGF-1 expression were observed in the spinal cord via postoperative immunostaining and the apoptosis of motor neurons was observed using the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling method. Pathological changes of the motor neurons and Nissl bodies within cell bodies were observed via Marsland and Luxol fast blue double staining, while changes in the neuropil of the spinal cord anterior horn were investigated via ultrastructural observation. It was found that hIGF-1, locally transfected into an area of peripheral nerve injury, was expressed in the spinal anterior horn following axoplasmic transport; the peak hIGF-1 expression occurred approximately a week following transfection. The number of apoptotic spinal cord motor neurons observed in the hIGF-1 treatment group was fewer than that in the sham-transfected and blank control groups at days 7, 14 and 21 following transfection (P<0.01). Furthermore, the quantity of motor neuron cells in the anterior horn of the spinal cord in the hIGF-1 treatment group was higher compared with those in the sham-transfected and blank control groups at days 2, 7, 14 and 28 following transfection (P<0.01). The degenerative changes of Nissl bodies within the cytoplasm of the hIGF-1 treatment group were less severe compared with those of the sham-transfected and blank control groups. At day 56 following transfection, the spinal anterior horn neuropil ultrastructure in the hIGF-1 treatment group was generally normal, while the sham-transfected and blank control groups exhibited an increased number of protruding gaps and local cavities. These results indicate that the application of exogenous hIGF-1 is capable of protecting spinal cord motor neurons following peripheral nerve injury.

Entities:  

Keywords:  human insulin-like growth factor-1; neuropil; peripheral nerve; spinal cord

Year:  2015        PMID: 26170906      PMCID: PMC4487006          DOI: 10.3892/etm.2015.2472

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  26 in total

1.  Direct gene transfer into nonhuman primate myofibers in vivo.

Authors:  S Jiao; P Williams; R K Berg; B A Hodgeman; L Liu; G Repetto; J A Wolff
Journal:  Hum Gene Ther       Date:  1992-02       Impact factor: 5.695

2.  [Small-gap bridging technology for peripheral nerve injury repair and the new sleeve material].

Authors:  Yu-hui Kou; Xiao-feng Yin; Pei-xun Zhang; Bao-guo Jiang
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2011-10-18

3.  Insulin and somatemedin MSA promote nerve growth factor-independent neurite formation by cultured chick dorsal root ganglionic sensory neurons.

Authors:  M Bothwell
Journal:  J Neurosci Res       Date:  1982       Impact factor: 4.164

4.  Insulin-like growth factor binding protein-3: factors affecting binary and ternary complex formation.

Authors:  S R Holman; R C Baxter
Journal:  Growth Regul       Date:  1996-03

5.  Direct gene transfer into mouse muscle in vivo.

Authors:  J A Wolff; R W Malone; P Williams; W Chong; G Acsadi; A Jani; P L Felgner
Journal:  Science       Date:  1990-03-23       Impact factor: 47.728

6.  Circulating IGF-I: New Perspectives for a New Century.

Authors: 
Journal:  Trends Endocrinol Metab       Date:  1999-05       Impact factor: 12.015

7.  [Effect of xiaokeling concentration fluid on mRNA expression of insulin-like growth factor-1 in sciatic nerve of Streptozotocin-induced diabetic rats].

Authors:  Jiang-zheng Zeng; Ke-li Dong; Guang-cheng Li; Liang-ming Li
Journal:  Zhong Nan Da Xue Xue Bao Yi Xue Ban       Date:  2005-02

8.  Effects of substance P and IGF-1 in corneal epithelial barrier function and wound healing in a rat model of neurotrophic keratopathy.

Authors:  Takashi Nagano; Masatsugu Nakamura; Katsuhiko Nakata; Takeshi Yamaguchi; Kenji Takase; Akihiko Okahara; Toshimi Ikuse; Teruo Nishida
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-09       Impact factor: 4.799

9.  Ciliary neurotrophic factor for acceleration of peripheral nerve regeneration: an experimental study.

Authors:  Jian Zhang; William C Lineaweaver; Tanya Oswald; Zhengrong Chen; Zhongwei Chen; Feng Zhang
Journal:  J Reconstr Microsurg       Date:  2004-05       Impact factor: 2.873

10.  Effects of insulin-like growth factor-I and platelet-rich plasma on sciatic nerve crush injury in a rat model.

Authors:  Erhan Emel; Selma Sönmez Ergün; Dilcan Kotan; Esra Başar Gürsoy; Yeşim Parman; Asli Zengin; Asiye Nurten
Journal:  J Neurosurg       Date:  2010-10-29       Impact factor: 5.115

View more
  3 in total

1.  Fresh human amniotic membrane effectively promotes the repair of injured common peroneal nerve.

Authors:  Zhong-Yuan Zhang; Jin Yang; Zhen-Hai Fan; Da-Li Wang; Yu-Ying Wang; Tao Zhang; Li-Mei Yu; Chang-Yin Yu
Journal:  Neural Regen Res       Date:  2019-12       Impact factor: 5.135

Review 2.  Insulin-Like Growth Factor-1: A Promising Therapeutic Target for Peripheral Nerve Injury.

Authors:  Benjamin R Slavin; Karim A Sarhane; Nicholas von Guionneau; Phillip J Hanwright; Chenhu Qiu; Hai-Quan Mao; Ahmet Höke; Sami H Tuffaha
Journal:  Front Bioeng Biotechnol       Date:  2021-06-24

3.  Catalpol prevents denervated muscular atrophy related to the inhibition of autophagy and reduces BAX/BCL2 ratio via mTOR pathway.

Authors:  Yuan Wang; Yali Shao; Yuqing Gao; Guoran Wan; Dong Wan; Huifeng Zhu; Yan Qiu; Xiyue Ye
Journal:  Drug Des Devel Ther       Date:  2018-12-31       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.